Pharmaceuticals

VELETRI Market Analysis Covering Growth Drivers And Future Outlook

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The VELETRI Market In 2026, And How Will Its Value Evolve By 2030?

The veletri market has experienced robust expansion in recent years. It is projected to increase from $1.45 billion in 2025 to $1.56 billion in 2026, registering a compound annual growth rate (CAGR) of 7.7%. Historically, this growth can be attributed to the clinical efficacy of epoprostenol, a rise in the diagnosis of PAH, hospitals’ reliance on IV prostacyclins, a limited number of oral alternatives, and improved PAH survival rates.

The veletri market is poised for significant growth over the next few years, with projections indicating it will reach $2.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. This anticipated expansion during the forecast period is primarily attributed to factors like the increasing prevalence of pah, the proliferation of specialty pah centers, a growing demand for stable formulations, wider adoption of infusion therapy, and improved awareness of pah. Prominent trends expected in this period include the increasing uptake of non-refrigerated prostacyclin therapies, expanded use of continuous infusion pah treatments, a rising demand for advanced pah vasodilators, the broadening of hospital-based pah management, and a heightened focus on enhancing pah patient mobility.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21314&type=smp

Which Strong Drivers Are Impacting The VELETRI Market Growth?

The VELETRI market is anticipated to grow as a result of the increasing prevalence of venous diseases. These conditions involve impaired blood flow in the veins, causing swelling, pain, and potential complications such as varicose veins and deep vein thrombosis. An aging population, sedentary lifestyles, obesity, and improved diagnostic capabilities are key factors contributing to the rising incidence of venous diseases. VELETRI is utilized to enhance exercise capacity and reduce symptoms in patients suffering from venous diseases that affect the pulmonary vasculature. For instance, in January 2025, the Centers for Disease Control and Prevention, a US-based government organization, reported that up to 900,000 individuals in the United States are affected annually by venous thromboembolism (VTE), a condition characterized by blood clots, with an estimated 60,000 to 100,000 fatalities attributed to VTE each year. Therefore, the growing prevalence of venous diseases is a significant driver of the VELETRI market’s expansion.

Which Segment Categories Are Included In The VELETRI Market Segment Analysis?

The veletri market covered in this report is segmented –

1) By Formulation Stability Type: Room-Temperature Stable Formulation, Refrigeration-Required Formulation

2) By Treatment Setting: Hospitals, Specialized Pulmonary Hypertension Centers

3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:

1) By Room-Temperature Stable Formulation: Ready-to-Use Formulation, Extended Stability Infusion Solution

2) By Refrigeration-Required Formulation: Reconstituted Cold-Chain Formulation, Limited-Stability Infusion Solution

Which Trends Are Guiding The Direction Of The VELETRI Market?

Leading companies in the Veletri market are concentrating on expanding access through generic formulations, such as FDA-approved epoprostenol sodium injection, to offer more economical treatment options for patients with pulmonary arterial hypertension. Generic Veletri refers to versions of the branded epoprostenol product that are therapeutically equivalent and meet FDA standards for quality, safety, and efficacy, delivering the same clinical benefits at a lower cost. For example, in October 2025, Mylan Pharmaceuticals, a US-based pharmaceutical company, obtained FDA approval for its generic Veletri (epoprostenol sodium) injection. This product is available in several vial strengths, including 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, and 200 mg/20 mL, and exhibits the same prostacyclin mimetic activity as the original version, aiding in the improvement of exercise tolerance and symptom management for PAH patients.

Who Are The Active Companies Shaping The VELETRI Market?

Major companies operating in the veletri market are Johnson & Johnson, Bayer Pharma AG, Novartis AG, GlaxoSmithKline plc, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Sun United Therapeutics Corporation, Actelion Pharmaceuticals Ltd., Bayer Pharma AG, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Johnson & Johnson, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Euroapi S.A., Pfizer CentreOne, Sai Life Sciences Limited, Zhejiang Ausun Pharmaceutical Co. Ltd., Yonsung Fine Chemicals Co. Ltd., Cayman Pharma S.r.o., Nichi-Iko Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals plc

Get The Full VELETRI Market Report:

https://www.thebusinessresearchcompany.com/report/veletri-global-market-report

Which Region Is The Top Contributor To The VELETRI Market By Share?

North America was the largest region in the VELETRI market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veletri market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized VELETRI Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/veletri-global-market-report

Browse Through More Reports Similar to the Global VELETRI Market 2026, By The Business Research Company

Vermiculite Market Report 2026

https://www.thebusinessresearchcompany.com/report/vermiculite-global-market-report

Vanadium Market Report 2026

https://www.thebusinessresearchcompany.com/report/vanadium-global-market-report

Gelatin Market Report 2026

https://www.thebusinessresearchcompany.com/report/gelatin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795